PLA 2.1 - Analyze Parallel-Line Assays and Parallel-Logistic Assays

May, 10th 2013. Stegmann Systems is proud to announce the availibilty of PLA 2.1 - a new major release of the PLA system. PLA 2.1 is focussed on the support of the new bioassay chapters of the US Pharmacopoeia (USP), now supporting both: USP and European Pharmacopoeia in one single solution.

 

PLA 2.1 is the standard solution for analyzing parallel-line and parallel-logistic (3-, 4- and 5-parameter logistic curve fits) biological assays according to the new US Pharmacopoeia bioassay chapters 1032, 1033 and 1034 as well as according to European Pharmacopoeia 6th Edition, Chapter 5.3 in one single GMP/GLP and 21 CFR part 11 compliant software.

Highlights:

• difference tests (F-Tests) and similarity testing (equivalence tests)
• mix difference testing and similarity testing in the same assay (optional)
• 32 different tests available - better control over the tests in your assay systems
• develop equivalence margins for similarity testing with PLA 2.1
• GMP/GLP compliant. FDA 21 CFR part 11 compliant.

Further Reading:

Key Feature of PLA 2.1
Key Benefits of PLA 2.1
What's new in PLA 2.1
Let our Experts Analyze Your Assay Data
Download a Fully Functional Trial of PLA 2.1

PLA 2.1 Product Brochure (PDF)
PLA 2.1 What's New? (PDF)